Onasemnogene abeparvovec (Zolgensma®)

Onasemnogene abeparvovec (Zolgensma®) was approved for reimbursement in Ireland on 8th October 2021 following joint assessment and negotiations under the Beneluxa Initiative. A Managed Access Protocol (MAP) is in place for onasemnogene abeparvovec which outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement.

The prescribing of onasemnogene abeparvovec (Zolgensma®) is confined to consultant neurologists with experience in the diagnosis and management of Spinal Muscular Atrophy (SMA) in specialist centre(s) in Ireland, who have agreed to the terms of the MAP and have been approved by the HSE.

The approved prescriber must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved prescribers.

A copy of the HSE-Managed Access Protocol for onasemnogene abeparvovec (Zolgensma®) approval and the application form for individual reimbursement can be found in the Related Files section below.

For further information, please contact mmp@hse.ie.

Click here for a Data Snapshot on treatments for SMA.